A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

ClinicalTrials.gov ID: NCT06431594

Public ClinicalTrials.gov record NCT06431594. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

Study identification

NCT ID: NCT06431594
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 675 participants

Conditions and interventions

Conditions

Interventions

Mocertatug rezetecan Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 1, 2024
Primary completion: Sep 21, 2027
Completion: Dec 30, 2029
Last update posted: Jun 24, 2026

2024 – 2029

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
GSK Investigational Site	Birmingham	Alabama	35294	Recruiting
GSK Investigational Site	Fountain Valley	California	92708	Recruiting
GSK Investigational Site	Santa Rosa	California	95403	Recruiting
GSK Investigational Site	Lake Mary	Florida	32746	Completed
GSK Investigational Site	Orlando	Florida	32827	Recruiting
GSK Investigational Site	Fairway	Kansas	66205	Recruiting
GSK Investigational Site	Boston	Massachusetts	02114	Recruiting
GSK Investigational Site	Boston	Massachusetts	02215	Recruiting
GSK Investigational Site	Detroit	Michigan	48201	Recruiting
GSK Investigational Site	Grand Rapids	Michigan	49546	Recruiting
GSK Investigational Site	Minneapolis	Minnesota	55455	Recruiting
GSK Investigational Site	Mineola	New York	11501	Recruiting
GSK Investigational Site	New York	New York	10016	Recruiting
GSK Investigational Site	Portland	Oregon	97213	Recruiting
GSK Investigational Site	Nashville	Tennessee	37203	Recruiting
GSK Investigational Site	Dallas	Texas	75230	Recruiting
GSK Investigational Site	West Valley City	Utah	84119	Recruiting
GSK Investigational Site	Seattle	Washington	98104	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06431594, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 24, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06431594 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →